Phase 2 Study of Fosbretabulin Tromethamine (CA4P) for the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic Pancreatic or Gastrointestinal Neuroendocrine Tumors/Carcinoid with Elevated Biomarkers

Libutti Steven K.; Anthony Lowell; Sosa Julie Ann; Kunz Pamela; Thomas James; Cruikshank Susan; Varga Alice; Chaplin David J.; Burke James; Wolin Edward M.

首页> 外文期刊>Pancreas >Phase 2 Study of Fosbretabulin Tromethamine (CA4P) for the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic Pancreatic or Gastrointestinal Neuroendocrine Tumors/Carcinoid with Elevated Biomarkers

【24h】

Phase 2 Study of Fosbretabulin Tromethamine (CA4P) for the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic Pancreatic or Gastrointestinal Neuroendocrine Tumors/Carcinoid with Elevated Biomarkers

机译：磷酸去氧肾上腺素氨丁三醇（CA4P）用于治疗分化程度高，中低级不可切除，复发或转移性胰腺或胃肠道神经内分泌肿瘤/类癌的生物标志物研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Pancreas》 |2016年第3期|共1页
作者
Libutti Steven K.; Anthony Lowell; Sosa Julie Ann; Kunz Pamela; Thomas James; Cruikshank Susan; Varga Alice; Chaplin David J.; Burke James; Wolin Edward M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Phase 2 Study of Fosbretabulin Tromethamine (CA4P) for the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic Pancreatic or Gastrointestinal Neuroendocrine Tumors/Carcinoid with Elevated Biomarkers [J] . Libutti Steven K., Anthony Lowell, Sosa Julie Ann, Pancreas . 2016,第3期

机译：磷酸去氧肾上腺素氨丁三醇（CA4P）用于治疗分化程度高，中低级不可切除，复发或转移性胰腺或胃肠道神经内分泌肿瘤/类癌的生物标志物研究
2. Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor [J] . Tetsuhide Ito, Takuji Okusaka, Toshirou Nishida, Investigational new drugs. . 2019,第3期

机译：矫正：II研究日本别人在日本患者中的不可切除或转移性，分化良好的胰腺神经内分泌肿瘤
3. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor [J] . ItoT., OkusakaT., NishidaT., Investigational new drugs. . 2013,第5期

机译：舒尼替尼在日本不可切除或转移性，分化良好的胰腺神经内分泌肿瘤患者中的II期研究
4. Efficacy and safety of sunitinib in Japanese patients with progressive advanced/metastatic well-differentiated unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study [O] . Tetsuhide Ito, Masayuki Tori, Satoshi Hashigaki, -1

机译：舒尼替尼在日本进行性晚期/转移性高分化不可切除的胰腺神经内分泌肿瘤患者的疗效和安全性：II期研究的最终分析
5. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study [O] . Tetsuhide Ito, Masayuki Tori, Satoshi Hashigaki, 2019

机译：日语患者在日本普通，晚期/转移性，良好分化，不可切除的胰腺神经内分泌肿瘤中的疗效和安全性：来自II期研究的最终分析

Phase 2 Study of Fosbretabulin Tromethamine (CA4P) for the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic Pancreatic or Gastrointestinal Neuroendocrine Tumors/Carcinoid with Elevated Biomarkers

著录项

相似文献

相关主题

期刊订阅